New Acqustions - Sun Pharmaceuticals Industries Ltd

Code BSE: 524715 NSE:

Sun Pharma will acquire Checkpoint Therapeutics, a company developing new cancer treatments. Sailent points are as below 1. The acquisition includes UNLOXCYT™, an FDA-approved treatment for advanced skin cancer. 2. Sun Pharma will pay $4.10 per share upfront, plus a contingent value right of up to $0.70 per share. 3. This is subject to shareholder approval and regulatory approvals. 4. Completion is expected in Q2 2025. 5. R&D expense for the same period was $19.3 million. 6. Cash balance as of September 30, 2024, was $4.7 million. 7. 𝗥𝗮𝘁𝗶𝗼𝗻𝗮𝗹𝗲 - a) Sun Pharma aims to enhance its global specialty product portfolio. b)- The acquisition will provide patients with access to UNLOXCYT™ in global markets.